TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05959720

Intervention type: DRUG
Intervention: Prednisone
Description: 60 mg/m2 D1 to D21

Intervention type: DRUG
Intervention: Vincristin
Description: 1.5 mg/m2 D1, D8, D15 and D22

Intervention type: DRUG
Intervention: Daunorubicin
Description: 40 mg/m2 D1, D8, D15 and D22

Intervention type: DRUG
Intervention: Peg-asparaginase
Description: 2000 UI/m2 D12 and D26

Intervention type: DRUG
Intervention: Intrathecal Suspension
Description: MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: 1000 mg/m2 D36 and D64

Intervention type: DRUG
Intervention: Cytarabine
Description: 75 mg/m2 D36 to D39, D43 to D46, D50 to D53 and D57 to D60

Intervention type: DRUG
Intervention: Mercaptopurine
Description: 30 mg/m2 D36 to D63 and D1 to D56 of consolidation

Intervention type: DRUG
Intervention: Methotrexate
Description: 3.000 mg/m2 D8, D22, D36 and D50

Intervention type: DRUG
Intervention: Doxorubicin
Description: 30 mg/m2 D1 and D22
Study: NCT05185661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth education
Description: eHealth education intervention regarding the dietary plan, healthy-lifestyle, and hygiene:~1. Group-wise eHealth education through online PowerPoint presentation session among study participants with their guardian: Two times (Before starting the intervention and mid-line; end of 4th-month intervention)~2. eHealth education through phone calls \& SMS~   * 1st to 4th month: 4 times in a month~  * 5th to 6th month: 3 times in a month~  * 6th to 8th month: 2 times in a month~3. Control group will not get care and education
Study: NCT06210217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine hydrochloride, Injectable
Description: In the dobutamine group, 3\~6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. The dose of dobutamine will be increased if the operating field grade exceeds Grade II. Monitoring LVEDV and SV with TEE to ensure preload: after admission, the patient will be given 3-4 mL /kg/h equilibrium fluid as background infusion. LVEDV and SV will be monitored using TEE every 30 minutes after anesthesia induction. If LVEDV\<75mL or SV\<45mL, 200mL colloidal fluid will be given within 5min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed. According to the currently commonly used principle of LCVP, the fluid will be limited to 3-4 ml /kg/h after anesthesia induction. If the operating field grade exceeds Grade II, nitroglycerin will be injected intravenously for remedial purposes at a rate of 0.3-0.8μg/kg/min.
Study: NCT06373952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online to offline counseling
Description: * Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online to offline counseling
Description: * Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment.
Study: NCT06282978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab (PF-06863135)
Description: The scheme of administration includes weekly administrations for at least six 4-weeks cycles and, if patients have achieved at least PR (or better) persisting for at least 2 months, the dose interval should be changed from weekly to every other week. Treatment will be scheduled with a response-adapted duration and patients achieving undetectable measurable residual disease (MRD) and maintained for 12 months will stop therapy. After stopping therapy, and if the patient is in sustained undetectable MRD for at least 12 months, it would be possible to re-start treatment with elranatamab in case the MRD will be detectable or relapse from CR will occur. Patients who will not achieve undetectable MRD sustained for 12 months will receive continuous treatment until progressive disease.
Study: NCT04816552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHoBI7 mHealth program Arm
Description: We will start delivery of this intervention with a pictorial module delivered in the home during two 30 minute visits on cholera transmission and prevention after enrollment. Households will be provided a handwashing station, a covered water vessel, and chlorine tablets. Households will then receive the CHoBI7 WASH mHealth program voice and text messages on handwashing with soap and water treatment bi-weekly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: general message on oral rehydration solution (ORS)
Description: general message on oral rehydration solution (ORS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general message on oral rehydration solution (ORS)
Description: general message on oral rehydration solution (ORS)
Study: NCT05854238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIRA-VoM
Description: treat persistent atrial fibrillation~* The ablation temperature range is 50-60℃~* About 2 minutes per ablation
Study: NCT06515730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 5 mg tablet twice a daily with dose reduction according to label

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: 2.5 mg tablet once daily, with individual dosing according to coagulation tests
Study: NCT05414058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apo-Methylphenidate ER
Description: For inpatients, the study medication will be administered by unit nurses, alongside their other medications. For outpatients, the study medication will be dispensed to the participant by the research assistant during their weekly visit. Patients will continue their regular medications as per standard of care.
Study: NCT05434416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions
Study: NCT05862649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuraLight
Description: NeuraLight software-based platform
Study: NCT05305404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: 1.5mg oral dexamethasone to be administered once at 11:00PM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo to be administered once at 11:00PM
Study: NCT05808829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Exercise
Description: University students did progressive muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, exercise was done with the researcher by online interview via Zoom.
Study: NCT05004441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib Combined With mFOLFOX6/FOLFIRI
Description: Fruquintinib (3mg) will be given p.o. daily
Study: NCT00751517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study: NCT06255431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezerra cream
Description: The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezerra cream
Description: The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen.
Study: NCT05542719

Intervention type: OTHER
Intervention: application
Description: Through the application, determine if the patient is out of LDL-C goals for referral and treatment review.~Show the usefulness of the application in achieving dyslipidemia treatment goals in patients with high and extremely high cardiovascular risk
Study: NCT05378750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diuretic algorithm
Description: Implementing diuretic algorithm
Study: NCT05106400

Intervention type: DRUG
Group type: OTHER
Intervention: ZTlido (Lidocaine Topical System) 1.8%
Description: 1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Salonpas (Lidocaine Patch 4%)
Description: 1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Aspercreme (Lidocaine Patch 4%)
Description: 1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours

Intervention type: DRUG
Group type: OTHER
Intervention: IcyHot (Lidocaine 4% + Menthol 1% Patch)
Description: 1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
Study: NCT05670886

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery ligation
Description: The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally Lower uterine incision was done followed by fetal extraction and placental delivery . bilateral uterine artery ligation were done 2cm below the uterine incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine artery ligation
Description: The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally Lower uterine incision was done followed by fetal extraction and placental delivery . bilateral uterine artery ligation were done 2cm below the uterine incision.
Study: NCT06151457

Intervention type: DRUG
Group type: OTHER
Intervention: Alpha-Agonist
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: OTHER
Intervention: α-adrenergic receptor agonist
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT04727307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (neoadjuvant)
Description: Atezolizumab 1200mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in neoadjuvant, for 2 cycles. The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 (± 10) minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Radiofrequency
Description: Any RFA system (uni/multi-needle, monopolar or multi-bi-polar) is allowed. Microwave ablation or irreversible electroporation is not allowed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Radiofrequency
Description: Any RFA system (uni/multi-needle, monopolar or multi-bi-polar) is allowed. Microwave ablation or irreversible electroporation is not allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (adjuvant)
Description: Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle in adjuvant, for 15 cycles maximum. The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 (± 10) minutes then over 30 (± 10) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (adjuvant)
Description: Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in adjuvant, for 15 cycles maximum. The dose will be delivered over 30 (± 10) minutes.
Study: NCT04852926

Intervention type: OTHER
Intervention: Self-administered questionnaires
Description: 6 self-administered questionnaires (EORTC-QLQ-C30, RSE, BIS, HAD, FSFI, DAS-4) completed by the patients at every usual follow-up consultation.~1 (FSFI) or 2 (MSHQ, PEP) self-administered questionnaires completed by the partner (respectively female or male) between every usual follow-up consultation.~Follow-up usual consultations :~* T0 (at inclusion) : before disease + since diagnosis~* C4 (chemotherapy course n°4)~* C6 (chemotherapy course n°6)~* M3 (3 months after chemotherapy)~* M6 (6 months after chemotherapy)~* A1 (1 year after chemotherapy)~* A2 (2 years after chemotherapy)
Study: NCT05513794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Imaging
Description: Neuromelanin sequence imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Imaging
Description: Neuromelanin sequence imaging
Study: NCT04318353

Intervention type: OTHER
Intervention: early enteral feeding within 2 days postoperative
Description: Enteral feeding within 2 days postoperative
Study: NCT05119361

Intervention type: OTHER
Intervention: Early Dry protocol
Description: After meeting eligibility criteria, patients have a net ultrafiltration of 2mL/kg/h with systematic perfusion monitoring (lactate concentration, central venous saturation, mottling score and capillary refill time) and restrictive input.~If the patient presents hypoperfusion (at least to sign), net ultrafiltration is stopped and haemodynamic optimized.~If the patient presents pulmonary oedema or right ventricular failure, with venous congestion, ultrafiltration is set at 3mL/kg/h.~Ultrafiltration is set between 0.5 and 1mL/kg/h when the following criteria are fulfilled: weight inferior to the admission weight; central venous pressure inferior to 5mmHg; absence of clinical oedema.~The haemodynamic status is reevaluated all six hours.

Intervention type: OTHER
Intervention: Early Dry protocol
Description: After meeting eligibility criteria, patients have a net ultrafiltration of 2mL/kg/h with systematic perfusion monitoring (lactate concentration, central venous saturation, mottling score and capillary refill time) and restrictive input.~If the patient presents hypoperfusion (at least to sign), net ultrafiltration is stopped and haemodynamic optimized.~If the patient presents pulmonary oedema or right ventricular failure, with venous congestion, ultrafiltration is set at 3mL/kg/h.~Ultrafiltration is set between 0.5 and 1mL/kg/h when the following criteria are fulfilled: weight inferior to the admission weight; central venous pressure inferior to 5mmHg; absence of clinical oedema.~The haemodynamic status is reevaluated all six hours.
Study: NCT04814004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCD19.IL15.CAR-iNKT
Description: Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.
Study: NCT05185869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390, Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Paclitaxel-albumin, Intravenous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, Intravenous Injection
Study: NCT05038982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Description: During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Description: During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
Study: NCT05513404

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honeyberry
Description: To investigate changes in postprandial glucose and cognitive performance, after consumption of honeyberries grown in Scotland.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry
Description: To investigate changes in postprandial glucose and cognitive performance, after consumption of cherries grown in Scotland.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry
Description: To investigate changes in postprandial glucose and cognitive performance, after consumption of raspberries grown in Scotland.
Study: NCT06080841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin + Piperine
Description: Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin + Piperine
Description: Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin + Piperine
Description: Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.